News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sequenta, Inc. Collaborators to Present Five Studies Showing the Power of Lymphosight™ Minimal Residual Disease Platform at European Hematology Association



6/12/2013 9:14:24 AM

STOCKHOLM – Sequenta, Inc. announced today that its collaborators will present studies at the 18th Congress of the European Hematology Association (EHA) here this week demonstrating the superiority of the company’s LymphoSIGHT™ technology in detecting minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and multiple myeloma (MM).

These studies, combined with previous data presented at the American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) annual meetings, show that Sequenta’s LymphoSIGHT platform represents a highly reliable method for detecting MRD in marrow and blood.

“Sequenta’s groundbreaking use of next-generation sequencing to detect and monitor immune cells continues to demonstrate improvements over standard MRD methods across a full range of lymphoid malignancies,” said Tom Willis, Sequenta’s CEO. “The independent validation of the LymphoSIGHT technology by many collaborators has now clearly established our platform as the emerging standard for molecular MRD detection and is the result of the steadfast company commitment to uncompromising, peer-reviewed clinical science.”

Relative to competing platforms, the LymphoSIGHT method offers significant advantages in sensitivity and reproducibility across patients, as well as the ability to follow heterogeneous cancers, including those that have significant rates of mutation before and after diagnosis. All of these technical features translate into a superior ability to predict ultimate relapse.

Earlier this year Sequenta launched its ClonoSIGHT™ test through its CLIA certified facility in South San Francisco. The ClonoSIGHT test utilizes the LymphoSIGHT platform and is the first clinically actionable sequencing-based MRD test. The studies being presented at EHA are:

A COMPARATIVE ANALYSIS OF NEXT-GENERATION SEQUENCING AND REAL-TIME QUANTITATIVE PCR FOR MINIMAL RESIDUAL DISEASE DETECTION IN FOLLICULAR LYMPHOMA

Abstract code: P291

Date and Time: 6/14/2013 5:45PM

Location: Poster Hall

MINIMAL RESIDUAL DISEASE (MRD) DETECTION BY NEXT-GENERATION SEQUENCING AND REAL-TIME QUANTITATIVE PCR: A METHODICAL COMPARISON IN ALL, MCL AND MM

Abstract code: P293

Date and Time: 6/14/2013 5:45PM

Location: Poster Hall

PROGNOSTIC VALUE OF DEEP SEQUENCING METHOD FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA

Abstract code: P237

Date and Time: 6/14/2013 5:45PM

Location: Poster Hall

A COMPARISON BETWEEN NEXT-GENERATION SEQUENCING AND ASO-QPCR FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA

Abstract code: P235

Date and Time: 6/14/2013 5:45PM

Location: Poster Hall

COMPARISON OF NEXT-GENERATION SEQUENCING AND ASO-PCR METHODS FOR MRD DETECTION IN ACUTE LYMPHOBLASTIC LEUKEMIA

Abstract code: S537

Date and Time: 6/15/2013 8:30AM

Location: Hall A4/A5

COMPARISON OF NEXT-GENERATION SEQUENCING AND ASO-PCR METHODS FOR MRD DETECTION IN MANTLE CELL LYMPHOMA

Abstract code: P833

Date and Time: 6/15/2013 5:45PM

Location: Poster Hall

About Sequenta, Inc.

Sequenta is a venture backed startup dedicated to improving patient care in diseases mediated by immune cells through measurements of lymphocyte diversity. It is commercializing its LymphoSIGHT™ platform for clinical use in minimal residual disease while continuing to validate the use of its technology in a diverse set of diseases. For more information, go to www.sequenta.com.


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES